Neratinib Approved in Canada for Early-Stage HER2+ Breast Cancer

July 17, 2019 – Health Canada has approved neratinib for the extended adjuvant treatment of patients with early-stage, hormone receptor (HR)–positive, HER2-overexpressed/amplified breast cancer within 1 year after completing trastuzumab-based adjuvant therapy. The approval is based on findings from the phase III ExteNET trial, in which the 2-year invasive disease-free survival (iDFS) rate was 95.3% in those who received neratinib compared with 90.8% in the … (leggi tutto)